BCLS Fund IV Investments, L.P. → Kailera Therapeutics, Inc. KLRA

The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Adam Koppel, a Partner of BCLSI, is a member of the Issuer's board of directors (the "Board"). The Reporting Person acquired the securities reported herein for investment purposes. In its capacity as a significant stockholder of the Issuer, the Reporting Person intends to take an active role in working with the Issuer's management and the Board on operational, financial and strategic initiatives. The Reporting Person reviews and intends to continue to review, on an ongoing and continuing basis, their investment in the Issuer. Depending upon the factors discussed below and subject to applicable law, the Reporting Person may from time to time acquire additional securities of the Issuer or sell or otherwise dispose of some or all of their securities of the Issuer. Any transactions that the Reporting Persons may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Issuer, the financial condition, results of operations and prospects of the Issuer, general economic, financial market and industry conditions, other investment and business opportunities avialable to the Reporting Person, tax considerations and other factors.